Add and Subtract Therapy of Zhuye Shigao Tang Combined with Qingqi Huatan Pills on Chronic Obstructive Pulmonary Disease at Acute and Aggravating Period
|更新时间:2024-01-04
|
Add and Subtract Therapy of Zhuye Shigao Tang Combined with Qingqi Huatan Pills on Chronic Obstructive Pulmonary Disease at Acute and Aggravating Period
Chinese Journal of Experimental Traditional Medical FormulaeVol. 23, Issue 11, Pages: 190-195(2017)
ZHANG Wen-bin, LEI Wen-hui, FENG Ying-kai. Add and Subtract Therapy of Zhuye Shigao Tang Combined with Qingqi Huatan Pills on Chronic Obstructive Pulmonary Disease at Acute and Aggravating Period[J]. Chinese journal of experimental traditional medical formulae, 2017, 23(11): 190-195.
DOI:
ZHANG Wen-bin, LEI Wen-hui, FENG Ying-kai. Add and Subtract Therapy of Zhuye Shigao Tang Combined with Qingqi Huatan Pills on Chronic Obstructive Pulmonary Disease at Acute and Aggravating Period[J]. Chinese journal of experimental traditional medical formulae, 2017, 23(11): 190-195. DOI: 10.13422/j.cnki.syfjx.2017110190.
Add and Subtract Therapy of Zhuye Shigao Tang Combined with Qingqi Huatan Pills on Chronic Obstructive Pulmonary Disease at Acute and Aggravating Period
Objective: To discuss the clinical effect of modified therapy of Zhuye Shigao Tang combined with Qingqi Huatan pills in treating chronic obstructive pulmonary disease at acute exacerbation stage (AECOPD) with syndrome of phlegm-heat obstructing lung and investigate its effect on levels of hypersensitive C-reactive protein (hs-CRP)
copeptin (CPP)
serum amyloid A (SAA)
nuclear factor-κB (NF-κB) and procalcitonin (PCT). Method: One hundred and sixty-six AECOPD patients were randomly divided into control group (83 cases) and observation group (83 cases) by random number table. Patients in control group took oxygen therapy by referring to the guide. Received ceftezole sodium injection by intravenous infusion
2 g/time
2 times/day by oral administration. Prednisolone tablets
10 mg/time
3 times/day. And ipratropium bromide aerosol
3-4 times/day
2 sprays/time. Based on the treatment in control group
the patients in observation group also received modified therapy of Zhuye Shigao Tang combined with Qingqi Huatan pills. The treatment course was 14 days for both groups. The main outcome measures were COPD patients self-assessment test questionnaire (CAT)
modified version of the British Medical Research Council's Respiratory Questionnaire (mMRC)
and scores of phlegm-heat obstructing lung syndrome. The secondary indicators were arterial blood gas analysis [blood oxygen (PaO2)
carbon dioxide partial pressure (PaCO2)
oxygen saturation (SaO2) and pH value] and pulmonary function [forced expiratory volume in 1 second (FEV1) and 1 second forced expiratory volume in percent predicted (FEV1%)]. In addition
the levels of hs-CRP
CPP
SAA
NF-κB and PCT were detected. All of the above indicators were detected once before and after treatment. Result: The total clinical effective rate was 94.87% in observation group
higher than 83.54% in control group (χ2=4.721
P<0.05). After treatment
scores of CAT
mMRC and syndrome of phlegm-heat obstructing lung in observation group were all lower than those in control group (P<0.01). Levels of PaCO2,hs-CRP
CPP
SAA
NF-κB and PCT were lower than control group. And the levels of PaO2
SaO2
FEV1 and FEV1% were higher than those in control group (P<0.01)
but there was no statistically significant difference in pH value between two groups. Conclusion: Based on the basic western medicine treatment
modified therapy of Zhuye Shigao Tang combined with Qingqi Huatan pills can control the symptoms and infection
ameliorate pulmonary function
reduce inflammation
and improve the clinical efficacy in patients with AECOPD and syndrome of phlegm-heat obstructing lung.
Clinical Observation of Dizhuo Huatan Decoction on AECOPD with Syndrome of Phlegm and Blood Stasis Obstructing Lung
Connotation of Traditional Chinese Medicine's Protection of Pulmonary Microvascular Endothelial Cells in Prevention and Treatment of Chronic Obstructive Pulmonary Disease Based on "Lung Collateral Theory"
Traditional Chinese Medicine Intervention of Signaling Pathways in Chronic Obstructive Pulmonary Disease: A Review
Mechanism of Modified Erchentang on COPD Inflammation Based on TNF-α/TNFR1/RIPKs Pathway
Effect of Xuanfei Zhisou Prescription on IL-17 Signaling Pathway in COPD Model Rats
Related Author
HE Yan-zhong
ZHOU Miao
XIN Jingjing
WANG Tongxing
HAN Ningxin
YANG Yang
LI Zhuying
TIAN Chunyan
Related Institution
Key Laboratory of State Administration of Traditional Chinese Medicine (Cardio-Cerebral Vessel Collateral Disease)
State Key Laboratory for Innovation and Transformation of Luobing Theory
Graduate School, Hebei Medical University
First Affiliated Hospital, Heilongjiang University of Chinese Medicine